Buy Persantine Online

Persantine (dipyridamole)

THERAPEUTIC CLASS

Platelet aggregation inhibitor

DEA CLASS

RX

INDICATIONS

Adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.

ADULT DOSAGE

Prevention of Thromboembolic Events

Adjunct to coumarin anticoagulants in the prevention of postoperative complications of cardiac valve replacement

75-100mg qid as adjunct to warfarin therapy

PEDIATRIC DOSAGE

Prevention of Thromboembolic Events

Adjunct to coumarin anticoagulants in the prevention of postoperative complications of cardiac valve replacement

≥12 Years:
75-100mg qid as adjunct to warfarin therapy

ADMINISTRATION

Oral route

HOW SUPPLIED

Tab: 25mg, 50mg, 75mg

WARNINGS/PRECAUTIONS

Caution with hypotension and severe coronary artery disease (CAD) (eg, unstable angina or recently sustained myocardial infarction). May aggravate chest pain with underlying CAD. Elevated hepatic enzymes and hepatic failure reported.

ADVERSE REACTIONS

Dizziness, abdominal distress, headache, rash.

DRUG INTERACTIONS

Increases plasma levels and cardiovascular effects of adenosine; may need dose adjustment of adenosine. May counteract effects of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

PREGNANCY AND LACTATION

Category B, caution in nursing.

MECHANISM OF ACTION

Platelet aggregation inhibitor; inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes. Inhibition results in an increase in adenosine concentrations which acts on the platelet A2 receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate levels. Platelet aggregation is thereby inhibited in response to various stimuli (eg, platelet activating factor, collagen, adenosine diphosphate). Also, inhibits phosphodiesterase (PDE) in various tissues. Inhibits cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), which thereby augments the increase in cGMP produced by endothelium-derived relaxing factor (nitric oxide).

PHARMACOKINETICS

Absorption: Tmax=75 min. Distribution: Highly bound to plasma proteins; found in breast milk. Metabolism: Liver (conjugation). Elimination: Bile; T1/2=10 hrs.

ASSESSMENT

Assess for hepatic function, hypotension, severe CAD, pregnancy/nursing status, and for possible drug interactions.

MONITORING

Monitor for elevations of hepatic enzymes, hepatic failure, chest pain in patients with CAD, and other adverse reactions.

PATIENT COUNSELING

Inform about the risks/benefits of therapy. Instruct to take as prescribed. Advise to contact physician if any signs/symptoms of hepatic insufficiency develop. Inform that aspirin should not be administered concomitantly with coumarin anticoagulants.

STORAGE

25°C (77°F); excursions permitted to 15-30°C (59-86°F).

TAGS

dipyridamole mr, persantine 25 mg, buy persantine, dipyridamole persantine, adenosine dipyridamole, dipyridamole 25 mg, persantine price, persantine tablets, persantine 50 mg, persantine iv, dipyridamole aspirin, dipyridamole and aspirin, aspirin dipyridamole, dipyridamole tablets, persantine 75 mg, dipyridamole 50 mg, dipyridamole 75 mg, aspirin and dipyridamole, order persantine, buy dipyridamole, dipyridamole 200 mg, dipyridamole 200mg